TY - JOUR
T1 - Clinical characteristics of cytochrome p450 oxidoreductase deficiency
T2 - A nationwide survey in japan
AU - Yatsuga, Shuichi
AU - Amano, Naoko
AU - Nakamura-Utsunomiya, Akari
AU - Kobayashi, Hironori
AU - Takasawa, Kei
AU - Nagasaki, Keisuke
AU - Nakamura, Akie
AU - Nishigaki, Satsuki
AU - Numakura, Chikahiko
AU - Fujiwara, Ikuma
AU - Minamitani, Kanshi
AU - Hasegawa, Tomonobu
AU - Tajima, Toshihiro
N1 - Funding Information:
We thank all physicians and patients with PORD for providing us with clinical data. This work was supported by members of the mass screening committee for the Japanese Society for Pediatric Endocrinology and by members of the adrenal committee of the Japanese Society for Pediatric Endocrinology. We thank Tamara Leahy, PhD and Angela Morben, DVM, ELS, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.
Publisher Copyright:
© The Japan Endocrine Society.
PY - 2020
Y1 - 2020
N2 - Cytochrome P450 oxidoreductase deficiency (PORD) is a disorder of steroidogenesis that causes various symptoms such as skeletal malformations, disorders of sex development, and adrenal insufficiency. The aim of this study was to elucidate the clinical characteristics, especially age at diagnosis and treatment, of PORD from the perinatal period to adulthood in Japan. The first questionnaire was sent to 183 council members of the Japanese Society for Pediatric Endocrinology on 1 September 2018. The response rate was 65%, and a total of 39 patients with PORD were examined at 20 hospitals. The second questionnaire was sent in November 2018 to the council members examining these 39 patients with PORD. The response rate was 77%, and we received clinical information on 30 of the 39 patients. The two novel clinical findings were the age at diagnosis and the treatment of Japanese patients with PORD. In many cases, PORD can be diagnosed at <3 months of age. Hydrocortisone as the primary treatment during infancy can be used daily or in stressful situations; however, because patients with PORD generally have mild to moderate adrenal insufficiency, some might be able to avoid hydrocortisone treatment. Patients with PORD should be carefully followed up, and treatment should be optimized as for patients with other types of adrenal insufficiency. Other characteristics in the present study were similar to those described in previous reports.
AB - Cytochrome P450 oxidoreductase deficiency (PORD) is a disorder of steroidogenesis that causes various symptoms such as skeletal malformations, disorders of sex development, and adrenal insufficiency. The aim of this study was to elucidate the clinical characteristics, especially age at diagnosis and treatment, of PORD from the perinatal period to adulthood in Japan. The first questionnaire was sent to 183 council members of the Japanese Society for Pediatric Endocrinology on 1 September 2018. The response rate was 65%, and a total of 39 patients with PORD were examined at 20 hospitals. The second questionnaire was sent in November 2018 to the council members examining these 39 patients with PORD. The response rate was 77%, and we received clinical information on 30 of the 39 patients. The two novel clinical findings were the age at diagnosis and the treatment of Japanese patients with PORD. In many cases, PORD can be diagnosed at <3 months of age. Hydrocortisone as the primary treatment during infancy can be used daily or in stressful situations; however, because patients with PORD generally have mild to moderate adrenal insufficiency, some might be able to avoid hydrocortisone treatment. Patients with PORD should be carefully followed up, and treatment should be optimized as for patients with other types of adrenal insufficiency. Other characteristics in the present study were similar to those described in previous reports.
KW - Adrenal insufficiency
KW - Cytochrome P450 oxidoreductase deficiency
KW - Disorders of sex development
KW - Skeletal malformations
UR - http://www.scopus.com/inward/record.url?scp=85091808488&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091808488&partnerID=8YFLogxK
U2 - 10.1507/endocrj.EJ20-0011
DO - 10.1507/endocrj.EJ20-0011
M3 - Article
C2 - 32321882
AN - SCOPUS:85091808488
SN - 0918-8959
VL - 67
SP - 853
EP - 857
JO - Endocrine Journal
JF - Endocrine Journal
IS - 8
ER -